Correction to: BMC Genomics 23, 20 (2022)

https://doi.org/10.1186/s12864-021-08214-9

Following publication of the original article [1], it was reported that there was an error in the presentation of Lin Xu and Guo-Bao Tian’s affiliations in the PDF version of the article. Furthermore, the authors reported a typographical error in the sub-section ‘Antimicrobial susceptibility testing’. The correction is highlighted in bold.

The incorrect sentence was:

“Minimum inhibitory concentrations (MICs) were determined for the following 17 diferent antibiotics: cefotaxime (CTX), ceftazidime (CAZ), cefepime (FEP), colistin (CT), tigecycline (TGC), imipenem (IMP), ertapenem (ETP), meropenem (MEM), ciprofoxacin (CIP), fosfomycin (FOS), trimethoprim-sulfamethoxazole (SXT), piperacillin-tazobactam (PTZ), amikacin (AMK), gentamicin (GEN), chloramphenicol (CHL), tetracycline [5], and aztreonam (ATM) for EBSI041 using the agar microdilution method excepted for colistin using the broth microdilution method.”

The correct sentence is:

Minimum inhibitory concentrations (MICs) were determined for the following 17 diferent antibiotics: cefotaxime (CTX), ceftazidime (CAZ), cefepime (FEP), colistin (CT), tigecycline (TGC), imipenem (IMP), ertapenem (ETP), meropenem (MEM), ciprofoxacin (CIP), fosfomycin (FOS), trimethoprim-sulfamethoxazole (SXT), piperacillin-tazobactam (PTZ), amikacin (AMK), gentamicin (GEN), chloramphenicol (CHL), tetracycline (TET), and aztreonam (ATM) for EBSI041 using the agar microdilution method excepted for colistin using the broth microdilution method.

The correct affiliations presentation is given in this Correction article and the original article [1] has been updated.